Connection
Elaine Lam to Prospective Studies
This is a "connection" page, showing publications Elaine Lam has written about Prospective Studies.
|
|
Connection Strength |
|
 |
|
 |
|
0.058 |
|
|
|
-
Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barth?l?my P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albig?s L, Harshman LC, Choueiri TK. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2021 Dec 01; 7(12):1815-1823.
Score: 0.022
-
Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Su?rez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis E, Powles T. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int. 2020 07; 126(1):73-82.
Score: 0.020
-
Hoffmann FA, Trenova A, Llaneza MA, Fischer J, Lus G, von Bredow D, Lara N, Lam E, Van Hoef M, Bakshi R. Patient satisfaction with ExtaviPro? 30G, a new auto-injector for administering interferon ?-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study. BMC Neurol. 2017 Aug 09; 17(1):156.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|